R.PR
REGISTERED-PRINCIPAL REGISTER
05/10/2021
Voltar para busca
Dado oficial do USPTO
EPSILOGEN
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: Estados Unidos
Snapshot rápido
EPSILOGEN
ST13
US500000088885762Classe
5, 42, 44
Pedido
88885762
Registro
6505086
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
15
Atualização mais recente
05/10/2021
Tipo de marca
Verbal
Classes Nice
5, 42, 44
Data de depósito
24/04/2020
Data de registro
05/10/2021
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
05/10/2021
Última transação
05/10/2021
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use, Foreign priority
Código do desenho
4
Tipo de titular
99
Localização do titular
London, GB
Examinador
RADEMACHER, APRIL
Unidade examinadora
L80
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Epsilogen Ltd
Representantes
Susan Piascik Christoff COOLEY LLP
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical drugs for suppressing tumors; pharmaceutical drugs for treating malignant tumors; pharmaceutical drugs for the treatment of cancer; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for use in oncology; anti-cancer drugs; anti-cancer preparations; anti-cancer preparations of plant origin; anti-cancer preparations of chemical origin; compounds for treating cancer; tumor suppressing agents; immunostimulants; medicine for suppressing tumors; medicine for treating malignant tumors; medicine for the treatment of cancer; diagnostic reagents for medical laboratory use
Classe 42
Scientific and technological servicesscientific research in the field of pharmaceutical research and development and research and design relating thereto; pharmaceutical drug development services; pharmaceutical research and development; scientific laboratory services; medical research laboratory services; laboratory research services relating to pharmaceuticals; clinical research in the field of cancer treatment; clinical trials for others; conducting clinical trials for others in the field of pharmaceutical products; providing medical and scientific research information about the results of clinical trials for pharmaceutical products; scientific research for medical purposes in the area of cancerous diseases; research and development services of technology in the fields of oncologyimmunology and immuno-oncology
Classe 44
Medical treatment services of cancerous diseases; medical screening of cancerous diseases; medical diagnostic monitoringtestinganalysis services; medical servicesdiagnosis and treatment of cancerous diseases; pharmaceutical servicesdispensing pharmaceuticals; pharmaceutical servicespharmaceutical consultation; pharmaceutical servicespharmaceutical compounding services; pharmaceutical advisory services; laboratory analysis services relating to the treatment of persons by medical laboratories; laboratory analysis services relating to the diagnosis and treatment of cancerous diseases by medical laboratories; providing cancer screening services; medical analysis services for cancer diagnosis and prognosis; RNA or DNA analysis for cancer diagnosis and prognosis by medical laboratories; medical services in the field of oncologyimmunology and immuno-oncology; providing advice relating to oncologyimmunology and immuno-oncology; providing on-line information relating to oncologyimmunology and immuno-oncology
Publicações
Histórico de despachos e eventos da marca no USPTO.
15 publicações encontradas
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
20/07/2021
PUBO
PUBLISHED FOR OPPOSITION
20/07/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
30/06/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
15/06/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/05/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/05/2021
ALIE
ASSIGNED TO LIE
04/05/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
21/01/2021
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
23/07/2020
GNRT
NON-FINAL ACTION E-MAILED
23/07/2020
CNRT
NON-FINAL ACTION WRITTEN
23/07/2020
DOCK
ASSIGNED TO EXAMINER
20/07/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/05/2020
NWAP
NEW APPLICATION ENTERED
28/04/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace EPSILOGEN ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.